

FDA clearance for breast cancer analysis platform, 4/15

April 2015—Applied Spectral Imaging has received FDA clearance for its GenASIs HiPath image capture and analysis platform.

The ASI platform for immunohistochemistry samples integrates with existing lab microscopes and workflows, aiming to provide labs with a cost-effective solution for digital pathology. The platform is intended for use as an aid to pathologists in the quantitative analysis and scoring of HER2, estrogen receptor (SP1), progesterone receptor, and Ki67 (30-9) proteins in formalin-fixed, paraffin-embedded breast cancer tissue.

[Applied Spectral Imaging](#), 800-611-3466